-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E3TIOJ4p4XpaJ7ywNuKCnSHtVx/hikyg0YZGVgXXxjEaYmEWDAmXxr2y6S7nQN3n o/WY6dJXpePTItqtyCIQGw== 0000950103-04-001475.txt : 20041022 0000950103-04-001475.hdr.sgml : 20041022 20041022162143 ACCESSION NUMBER: 0000950103-04-001475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041020 FILED AS OF DATE: 20041022 DATE AS OF CHANGE: 20041022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ANKCORN MICHAEL F CENTRAL INDEX KEY: 0001226479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15943 FILM NUMBER: 041092116 MAIL ADDRESS: STREET 1: INVERESK RESEARCH GROUP, INC. STREET 2: 87 SENNEVILLE ROAD CITY: SENNEVILLE, MONTREAL STATE: A8 ZIP: H9X 3R3 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHARLES RIVER LABORATORIES INTERNATIONAL INC CENTRAL INDEX KEY: 0001100682 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061397316 BUSINESS ADDRESS: STREET 1: 261 BALLARDVALE STREET CITY: WILMINGTON STATE: MA ZIP: 01867 BUSINESS PHONE: 9786586000 MAIL ADDRESS: STREET 1: 251 BALLARDVALE ST CITY: WILMINGTON STATE: MA ZIP: 01887 FORMER COMPANY: FORMER CONFORMED NAME: CHARLES RIVER LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19991208 4 1 ankcorn_ex.xml X0202 4 2004-10-20 0 0001100682 CHARLES RIVER LABORATORIES INTERNATIONAL INC CRL 0001226479 ANKCORN MICHAEL F 251 BALLARDVALE STREET WILMINGTON MA 01887 0 1 0 0 Corporate Sr. Vice President Common Stock 2004-10-20 4 A 0 65515 0 A 65515 D Employee Stock Option (right to buy) 22.50 2004-10-20 4 A 0 7890 0 A 2013-06-28 Common Stock 7890 7890 D Employee Stock Option (right to buy) 29.97 2004-10-20 4 A 0 23670 0 A 2014-01-30 Common Stock 23670 23670 D Shares and options to purchase shares of Issuer common stock were acquired pursuant to the transactions contemplated by the Agreement and Plan of Merger dated as of June 30, 2004, by and among the Issuer, Inveresk Research Group, Inc. Indigo Merger I Corp. and Indigo Merger II LLC (successor to Indigo Merger II Corp.). Received in exchange for 136,490 shares of Inveresk common stock in connection with the Merger. 3,945 options are exercisable on each of 6/28/05 and 6/28/06. 7,890 options are exercisable on each of 1/30/05, 1/30/06 and 1/30/07. /s/ Rushna Heneghan as attorney-in-fact for Michael F. Ankcorn 2004-10-22 -----END PRIVACY-ENHANCED MESSAGE-----